Isam Nasr, director of pediatric trauma at Johns Hopkins, discusses his presentation on traumatic brain injury (TBI) that took place during the 2023 American Pediatric Surgical Association annual meeting. TBI is a significant health concern for the pediatric population, and it can result in long-term disability and cognitive impairment.
Hello, my name is Isa Nasser. I'm a pediatric surgeon at the Johns Hopkins Center and I'm also the director of the pediatric Trauma program. Today, I will be go going over the scientific presentation title, which is the Pharmacologic Coli Receptor for Inhibition ails early micro gliosis and astrogliosis and improve the cognitive outcomes following traumatic brain injury. Now, why is this research important and why do you care? TB I is a significant health concern in the pediatric population often resulting in a long term disability and cognitive impairment. Despite advancements in TV management, there's a notable absence FDA approved drug that effectively mitigate the progression of the disease. One critical aspect of chronic brain injury is the secondary neuro inflammatory response that occurs after the this response exacerbates brain damage contributes to long term neurological deficits, consequently leads to poor outcome. Addressing your inflammation is therefore essential for improving patient recovery and minimizing the impact of complications. For CB I briefly, our research uh focused on addressing the secondary neurop response that I described using a novel pharmacologic inhibitor of the to like four signaling. Back now, pr four is a key component of the innate immune system. This result there, you know, there's also a study demonstrated the effectiveness of the inhibition in halting this detrimental process. This is by then regulating the expression of the pro and I and down the aptos or cell death related gene like bad and back. Furthermore to except four inhibition results in the shift towards a more balanced immune response. We observed an increase in the anti-inflammatory population of troy and a decrease in the pro inflammatory population. In addition, the infiltrating monocyte displayed a phenotypic switch towards an anti inflammatory pheno. This was accompanied by a decrease in the expression of interferon regulatory factor sta. Now, through the reduction of neuro inflammation and the promotion of the favorable immune response. Pr four inhibition enhances myelination around the lesion and myelination is crucial for maintaining a functional neural surface. This was supported by a significant improvement in cognitive function and learning as well as memory. After a four inhibition. What do I hope for you to take away from us? Now, our findings emphasize the importance of targeting this neuro neuro pathways and the management of TB I until our four inhibitors offer a promising therapeutic approach clinically by attenuating inflammation, modulating the immune response and enhancing the my my Lation. And by utilizing TL four inhibitors, we have the potential to enhance patient care to transform the lives of those affected by this devastating condition. I wanna thank you for watching my presentation. I appreciate your support